Literature DB >> 11027433

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?

W Walter1, K Lingnau, E Schmitt, M Loos, M J Maeurer.   

Abstract

Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the beta-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1beta-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) alpha-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-gamma) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Malphabeta1 and Malphabeta2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-gamma-treatment; and lack of constitutive and IFN-gamma-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027433      PMCID: PMC2363595          DOI: 10.1054/bjoc.2000.1415

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12.

Authors:  K Lingnau; P Hoehn; S Kerdine; S Koelsch; C Neudoerfl; N Palm; E Ruede; E Schmitt
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

2.  Crystal structure of mouse H2-M.

Authors:  D H Fremont; F Crawford; P Marrack; W A Hendrickson; J Kappler
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

3.  HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.

Authors:  S Sartoris; M T Valle; A L Barbaro; G Tosi; T Cestari; A D'Agostino; A M Megiovanni; F Manca; R S Accolla
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

4.  Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation.

Authors:  S Agarwal; A Rao
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

5.  Proteases, processing, and thymic selection.

Authors:  P Cresswell
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

6.  Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY).

Authors:  M Becker-André; K Hahlbrock
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

7.  Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assays.

Authors:  G Haberhausen; J Pinsl; C C Kuhn; C Markert-Hahn
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

Review 8.  The role of CD4+ T cell responses in antitumor immunity.

Authors:  D M Pardoll; S L Topalian
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

9.  The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed.

Authors:  P R Wolf; S Tourne; T Miyazaki; C Benoist; D Mathis; H L Ploegh
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

Review 10.  Hemoglobins from bacteria to man: evolution of different patterns of gene expression.

Authors:  R Hardison
Journal:  J Exp Biol       Date:  1998-04       Impact factor: 3.312

View more
  11 in total

1.  Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.

Authors:  Janet F Piskurich; Carolyn A Gilbert; Brittany D Ashley; Mojun Zhao; Han Chen; Jian Wu; Sophia C Bolick; Kenneth L Wright
Journal:  Mol Immunol       Date:  2005-06-13       Impact factor: 4.407

2.  Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.

Authors:  Han Chen; Carolyn A Gilbert; John A Hudson; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2006-06-12       Impact factor: 4.407

3.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

4.  Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma.

Authors:  Lixiao Liu; Xuedan Du; Jintao Fang; Jinduo Zhao; Yong Guo; Ye Zhao; Chengyang Zou; Xiaojian Yan; Wenfeng Li
Journal:  J Inflamm Res       Date:  2021-09-27

5.  BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II.

Authors:  Gil Redelman-Sidi; Anna Binyamin; Anthony C Antonelli; Will Catalano; James Bean; Hikmat Al-Ahmadie; Achim A Jungbluth; Michael S Glickman
Journal:  Cancer Immunol Res       Date:  2022-10-04       Impact factor: 12.020

6.  Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression.

Authors:  Patricia J Champine; Jacob Michaelson; Bart C Weimer; Danny R Welch; Daryll B DeWald
Journal:  Clin Exp Metastasis       Date:  2007-09-25       Impact factor: 5.150

Review 7.  Oncolytic virus-mediated reversal of impaired tumor antigen presentation.

Authors:  Shashi A Gujar; Patrick W K Lee
Journal:  Front Oncol       Date:  2014-04-10       Impact factor: 6.244

Review 8.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

9.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

10.  Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation.

Authors:  Sushila A Toulmin; Chaitali Bhadiadra; Andrew J Paris; Jeffrey H Lin; Jeremy Katzen; Maria C Basil; Edward E Morrisey; G Scott Worthen; Laurence C Eisenlohr
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.